-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125

Benzinga·10/22/2026 15:38:39
Listen to the news
RBC Capital analyst Kendall Au maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $125.